Advances in the treatment of rheumatoid arthritis and the spondyloarthropathies

Future Rheumatology

Volumn 2, Issue 2, 2007, Pages 133-138

  Anandarajah, Allen ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ATACICEPT; ATLIZUMAB; CERTOLIZUMAB PEGOL; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; HUMAXCD20; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; OCRELIZUMAB; OFATUMUMAB; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INFUSION; DRUG RESEARCH; DRUG SAFETY; EARLY DIAGNOSIS; ENTERITIS; HODGKIN DISEASE; HUMAN; INFECTION RATE; JOINT RADIOGRAPHY; LYMPHOCYTE DEPLETION; LYMPHOMA; MONOTHERAPY; PATIENT CARE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; RISK REDUCTION; SIDE EFFECT; SPONDYLOARTHROPATHY; UNSPECIFIED SIDE EFFECT;

EID: 34249333839     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.2.2.133     Document Type: Conference Paper

References (49)

1. Anderson JJ, Wells G, Verhoeven AC et al.: Factors predicting response to treatment in rheumatoid arthritis. Arthritis Rheum. 43, 22-29 (2000).
2. Lard LR, Visser H, Speyer I et al.: Early versus delayed treatment in patients with recent onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am. J. Med. 111, 446-451 (2001).
3. van der Helm-Vanmil AH, le Cessie S, van Dongen H et al.: A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum. 56, 433-440 (2007).
4. van Dongen H, van Aken J, Lard LR et al.: Evidence for a window of opportunity in a double-blind randomized clinical trial in patients with undifferentiated arthritis: the probable rheumatoid arthritis: methotrexate versus placebo treatment (PROMPT) Study. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November 2006 (Abstract 657).
5. Grigor C, Capell H, Stirling A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263-269 (2004).
6. Grigor C, Stirling A, Baxter D, McCarey DW, Capell HA, Porter D: 5-year follow-up of the Trial of Tight Control for Rheumatoid Arthritis (TICORA) study. Presented at: ACR/ARHP Annual Scientific Meeting. Washington DC, USA, 10-15 November, 2006 (Abstract 677).
7. Irvine SA, Capell HA, Stirling A, Porter DR: A randomised controlled trial of step up therapy versus triple therapy in early active rheumatoid arthritis - the TEAR study. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 1308).
8. Wolfe F, Cush JJ, O'Dell JR et al.: Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J. Rheumatol. 28, 1423-1430 (2001).
9. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF et al.: Clinical and radiographic outcome of four diffirent treatment strategies in patients with early rheumatoid arthritis (BeSt study). Arthritis Rheum. 52, 3381-3390 (2005).
10. van der Kooij SM, Van Der Bijl AE, Allaart CF et al.: Remission induction in early rheumatoid arthritis (RA) with initial infliximab and methotrexate theraphy: the disease course after IFX discontinuation in the BeSt trial. Presented at: ACR/ARHP Annual Scientific Meeting. Washington DC, USA, 10-15 November, 2006 (Abstract 658).
11. Leirisalo-Repo M, Möttönen T, Hannonen P et al.: Does addition of infliximab to triple DMARD plus prednisolone therapy increase rate of remissions in patients with early active rheumatoid arthritis? A randomized double-blind placebo-controlled study. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 1309).
12. Dixon WG, Watson KD, Lunt M, Hyrich KL: Rates of myocardial infarction (MI) and cerebrovascular accident (CVA) in patients with rheumatoid arthritis (RA) treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 681).
13. Jacobsson LTH, Turesson C, Nilsson JA et al.: Treatment with TNF blockers is associated with reduced premature mortality in patients with rheumatoid arthritis. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 729).
14. Bongartz T, Sutton AJ, Sweeting MJ et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 295, 2275-2285 (2006).
15. Schneeweiss, S, Setoguchi S, Weinblatt ME et al.: Anti TNF α inhibitors and the risk of severe bacterial infection. Presented at: ACR/ARHP Annual Scientfic Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 729).
16. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag KG: Tumor necrosis factor-α antagonists increase the risk of hospitalization with a bacterial infection among rheumatoid arthritis patients. Presented at: ACR/ARHP Annual Scientific Meeting. Washington DC, USA, 10-15 November, 2006 (Abstract 1238).
17. Mariette X, Tubach F, Philippe Ravaud et al.: Lymphomas in patients treated with TNF blockers in the national French prospective RATIO study: 16 cases in 2 years with diversity of the histologic subtypes and no evidence of an increased risk. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 724).
18. Wolfe F: The association of new cases of cancer with biologic therapy. Presented at: ACR/ARHP Annual Scientific Meeting. Washington DC, USA, 10-15 November, 2006 (Abstract 1321).
19. Cohen SB, Emery P, Greenwald MW et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 54, 2793-2806 (2006).
20. Keystone E, Emery P, Peterfy CG et al.: Inhibition of joint structural damage with rituximab is not dependant on clinical response in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX Study). Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 1307).
21. Keystone E, Fleischmann RM, Emery P et al.: Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 725).
22. Dass S, Rawstron AC, Vital EM et al.: Highly sensitive B cell analysis predicts response to rituximab therapy in RA. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 2121).
23. Dass S, Coulthard L, Rawstron AC et al.: B cell levels in synovium predict efficacy of rituximab in RA better than those in peripheral blood. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 Novembet 2006 (Abstract 1981).
24. Genovese M, Breedveld FC, Emery P et al.: TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 726).
25. Kremer JM, Genant HK, Moreland LW et al.: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. Ann. Intern. Med. 144, 865-876 (2006).
26. Genovese MC, Becker JC, Schiff M et al.: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor-α inhibition. N. Engl. J. Med. 353, 1114-1123 (2005).
27. Westhovens R: Abatacept: the first-in-class costimulation blocker for the treatment of rheumatoid arthritis. Future Rheumatol. 1, 15-22 (2006).
28. Genovese MC, Schiff M, Luggen M et al.: Sustained efficacy and safety through 2 years in patients with rheumatoid arthritis (RA) in the long-term extension of the ATTAIN trial. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 498).
29. Kremer J, Westhovens RA, Russell A et al.: Long-term efficacy of abatacept through 2 years of treatment in rheumatoid arthritis patients in the AIM trial. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 506).
30. Weinblatt ME, Combe B, Birbara C et al.: Safety and patient-reported outcomes through 2 years of treatment with abatacept in rheumatoid arthritis patients receiving background disease-modifying antirheumatic drugs (DMARDs): the ASSURE Trial. Presented at: ACR/ ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 509).
31. Genant HK, Peterfy C, Westhovens R et al.: Non-progression of structural damage over 2 years with abatacept in rheumatoid arthritis patients with an inadequate response to methotrexate in the AIM trial. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 940).
32. Anandarajah A, Ritchlin C: Treatment update on spondyloarthropathy. Curr. Opin. Rheumatol. 17, 247-256 (2005).
33. Haibel H, Brandt HC, Song IH et al.: Methotrexate 20 mg s.c. in ankylosing spondylitis - no efficacy over 4 months treatment in an open label pilot study. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 1820).
34. Sieper J, Dijkmans BAC, van der Linden S et al.: Sustained efficacy and safety of patients with ankylosing spondylitis treated with etanercept: outcomes at 148-160 weeks of long term therapy. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 1120).
35. Baraliakos X, Listing J, Brandt J et al.: Persistent clinical efficacy and excellent safety over 5 years of treatment with the anti-TNFα agent infliximab in patients with ankylosing spondylitis. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 1812).
36. Brandt J, Haibel H, Reddig J et al.: Successful short term treatment of severe undifferentiated spondyloarthropathy with anti-tumor necrosis factor α monoclonal antibody infliximab. J. Rheumatol. 29, 118-122 (2002).
37. Jois RN, Leeder J, Gibb A et al.: Low-dose infliximab treatment for ankylosing spondylitis - clinically and cost-effective. Rheumatology 45, 1566-1599 (2006).
38. Inman RD, Shojania K, Keystone E et al.: Efficacy of lower dose infliximab in active ankylosing spondylitis - interim results of a Canadian study. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 1116).
39. van der Heijde D, Kivitz A, Schiff J et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54, 2136-2146 (2006).
40. van der Heijde D, Kivitz A, Schiff MH et al.: Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 2017).
41. Lambert RGW, Salonen DC, Rahman P et al.: Adalimumab reduces spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis (AS): 52-week magnetic resonance imaging (MRI) results from the Canadian AS study. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 2037).
42. Anandarajah AP, Ritchlin CT: Infliximab in psoriatic arthritis. Future Rheumatol. 2, 13-22 (2007).
43. Mease PJ, Gladman DD, Ritchlin CT et al.: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum. 52, 3279-3289 (2005).
44. Kavanaugh A, Antoni CE, Krueger GG et al.: Infliximab treatment dissociates the effect of CRP on radiographic progression in patients with psoriatic arthritis. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract L25).
45. Gladman DD, Mease PJ, Choy EHS, Ritchlin CT, Wang H, Sasso EH: Adalimumab radiographic efficacy in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use, and clinical response: subanalysis of ADEPT. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 205).
46. Van den Bosch F, Reece R, Manger B et al.: Adalimumab (HUMIRA®) is effective and safe in treating psoriatic arthritis (PsA) in real-life clinical practice: preliminary results of the STEREO trial. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 1810).
47. Antivalle M, Mutti A, Bertani L et al.: Long-term treatment of inflammatory bowel disease associated spondyloarthropathy with infliximab. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 1117).
48. Schiellerup P, Krogfelt K, Locht H: Strong indications that intestinal infection with E. coli can trigger reactive arthritis - results from a large case-case comparison study. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 1113).
49. Deal C, Barr WG, Harrington T et al.: US rheumatologist supply and demand: 2005-2006 Workforce study. Presented at: ACR/ARHP Annual Scientific Meeting. Washington, DC, USA, 10-15 November, 2006 (Abstract 99).